Accelerated underwriting (AUW) is the L&H industry's bet that a 47-year-old male term-life applicant for a $750,000 20-year level term policy can get a same-day bind decision without a paramed, without a venipuncture, and without an attending physician statement - using only the application, LexisNexis MVR, an Rx history pull, ECDIS attributes, and an MIB code check. The bet pays off when the carrier's accelerated-UW model (Munich Re's risk-assessment platform, Swiss Re Magnum, RGA AURA NEXT, or SCOR Velogica) approves 55-70% of clean cases at preferred-best or preferred rates, knocks out 18-22% to traditional underwriting for paramed and APS, and declines roughly 4-7% outright. The audit risk is concentrated in the knockouts and the declines. Every adverse decision must trace to a documented, human-reviewable reason code that survives NAIC Model Bulletin on Use of Artificial Intelligence by Insurers §4, Colorado Reg 10-1-1's algorithm-inventory expectation for life insurance, NY DFS Circular Letter 2024-7's proxy test, and FCRA §615 adverse-action notice requirements when consumer-report data drove the call. This lesson walks the 47-year-old applicant case through Magnum, AURA NEXT, and Velogica side-by-side, produces the knockout reason-code memo, drafts the FCRA pre-notice and adverse-action letter, and documents the protected-class proxy separation that the carrier's chief underwriter and chief compliance officer countersign before the file closes.

The 47-Year-Old Applicant Case File

James Cordero, 47-year-old male, non-tobacco self-reported, applies for a $750,000 20-year level term policy through a captive agent at a Top-25 mutual life carrier. Build is 6'0", 218 lbs (BMI 29.6). The application discloses statin use (atorvastatin 20mg, started 2021), an SSRI (sertraline 50mg, started 2023 for situational anxiety), no tobacco in seven years, social alcohol use (2-4 drinks per week), and no family history of cardiovascular disease before age 60. The carrier's accelerated-UW jet path requires the case to score acceptably across five data feeds: (1) LexisNexis MVR pulled under FCRA permissible purpose, (2) Rx history from Milliman IntelliScript with the applicant's HIPAA authorization, (3) MIB code check with applicant consent, (4) ECDIS attributes including LexisNexis Risk Solutions' public-records score and behavioral overlay, (5) the carrier's internal mortality-experience model.

The LexisNexis MVR returns two speeding violations in the last 36 months - 78 in a 55 (April 2024) and 71 in a 55 (October 2025) - both paid, no DUI, no suspension. The IntelliScript Rx pull returns the disclosed atorvastatin and sertraline plus one undisclosed prescription: lorazepam 0.5mg, dispensed twice in 2024 (24 tablets total) under a urology-practice prescriber's NPI. The MIB returns code 670 (cardiovascular impairment, severity unspecified) reported by a prior carrier in 2022 - a code the applicant did not disclose and the application did not surface through the medical-history questions. The ECDIS public-records score is in the 38th percentile against the carrier's reference book, driven primarily by the MVR plus two civil filings in 2018 that resolved without judgment. The internal mortality model returns a debit-equivalent of +85 points on the carrier's table-rating scale against the preferred-best threshold of -20 points.

How Magnum, AURA NEXT, and Velogica Score the Same File

The three dominant accelerated-UW platforms in the 2026 U.S. L&H market - Swiss Re Magnum, RGA AURA NEXT, and SCOR Velogica - are not interchangeable. Each platform encodes the reinsurer's mortality experience, its risk-classification philosophy, and its tolerance for accelerated-path leakage. Munich Re's risk-assessment platform plays a similar role on cases reinsured into Munich Re's facultative or automatic-acceptance treaties. A carrier with multi-reinsurer treaty structure may route the same case through two platforms and compare outputs as a quality check.

Swiss Re Magnum

Magnum's rules engine on James Cordero's file evaluates each data feed against the carrier's specific Magnum rule set. The two speeding violations within 36 months trigger Magnum's driving-rule debit of +30 mortality points and an automatic knockout from preferred-best to preferred, but not below preferred. The atorvastatin plus the carrier-reported lipid trend (inferred from the prescription dose and the applicant's age) maps to a +15-point debit at preferred and a referral-to-medical-director flag if the underwriter cannot resolve from the application alone. The sertraline at 50mg with no psychiatric hospitalization history maps to a small +5-point debit at preferred. The undisclosed lorazepam from a urology practice triggers Magnum's "non-disclosure" rule - not because lorazepam at 24 tablets over 12 months is itself mortality-material, but because non-disclosure inside the eligibility window invokes Magnum's two-year contestable-period documentation flag and routes the case to traditional underwriting. The MIB code 670 triggers Magnum's prior-carrier-reported-impairment knockout: the case is removed from the accelerated path and a paramed exam plus an APS request to the cardiologist of record become mandatory. Magnum's output is a structured JSON envelope with rule IDs (Magnum.Driving.36mo.SpeedingTwo, Magnum.Rx.Atorvastatin.Disclosed, Magnum.Rx.Lorazepam.Undisclosed, Magnum.MIB.670.PriorReport), debit values, and routing instructions: knock out of accelerated path, route to traditional UW, order paramed plus APS-cardiology.

RGA AURA NEXT

AURA NEXT (the 2026 evolution of RGA's AURA platform with the next-generation rules engine) evaluates the same five feeds with RGA's rule set. The driving-violation pattern triggers AURA's driving-debit ladder at +25 points and the preferred-class cap. The Rx panel evaluation differs from Magnum's: AURA cross-references the lorazepam against the urology-practice prescriber NPI and flags a likely off-label or undocumented chronic-anxiety pattern; AURA's rule routes the case to a structured follow-up question to the producer rather than an immediate knockout. The MIB 670 hit triggers AURA's prior-impairment-disclosure rule with the same outcome as Magnum - knockout to traditional underwriting, paramed plus APS. AURA NEXT's documentation output includes a per-rule confidence band: the MIB knockout is high-confidence; the lorazepam follow-up is medium-confidence; the atorvastatin acceptance at preferred is high-confidence. The confidence banding lets the underwriter triage which AURA outputs need a second look.

SCOR Velogica

Velogica's evaluation differs primarily in how it weights the ECDIS public-records score and the behavioral overlay. The 38th-percentile public-records score plus the two civil filings sit inside Velogica's "marginal-acceptable" band and produce no automatic knockout - Velogica's rule set treats unadjudicated civil filings as non-mortality-material absent a pattern. The driving violations produce a +28-point debit and the preferred-class cap. The MIB 670 produces the same knockout as Magnum and AURA. The lorazepam triggers Velogica's "Rx not disclosed on application" rule, which under SCOR's risk-classification philosophy routes the case to traditional UW for contestability documentation rather than for re-rating. Velogica's output is a structured XML envelope with SCOR rule IDs, a recommended-class field (in this case: Traditional UW, paramed plus APS-cardiology required), and a rationale-narrative block the carrier's case manager can paste into the file note.

The three platforms converge on the same operational outcome - knockout from the accelerated path to traditional underwriting with paramed and APS - but the rule citations, the debit math, and the documentation envelopes differ. The carrier's chief underwriter chooses one platform as the system of record per product and treaty; the audit trail rests on that platform's rule citations, not on a free-text underwriter narrative.

The Knockout Reason-Code Memo

The carrier's AUW knockout reason-code memo is the file artifact that documents the non-medical decision in a form that survives NAIC §4 audit. Structure: (1) Applicant identification - full name, DOB, application number, product, face amount, agent and writing carrier. (2) Data feeds consulted - LexisNexis MVR pull date, Milliman IntelliScript pull date, MIB inquiry date and codes returned, ECDIS attribute set with version stamp, internal mortality-model version. (3) Rule citations from the platform of record - Magnum.MIB.670.PriorReport, Magnum.Rx.Lorazepam.Undisclosed, Magnum.Driving.36mo.SpeedingTwo, with the debit values and routing instructions returned by the platform. (4) Knockout decision and routing - "Case removed from accelerated underwriting path; routed to traditional underwriting; paramedical exam required; APS-cardiology required from prior treating cardiologist of record per MIB 670 prior report; FCRA adverse-action notice not yet triggered (case continues; no adverse action against applicant at this stage)." (5) Protected-class proxy separation - explicit confirmation that race, color, religion, national origin, sex, marital status, sexual orientation, gender identity, age (within the actuarially supportable range), and disability were not inputs to the rules invoked; that the MVR, Rx, MIB, and ECDIS variables are actuarially justified mortality predictors documented in the carrier's filed underwriting guidelines; and that the ECDIS public-records score's contribution to the decision was zero (the score was within the acceptable band). (6) Underwriter and medical director sign-off lines.

The memo's protected-class-proxy section is the audit hot zone. NY DFS Circular Letter 2024-7 frames the proxy test as a requirement to identify any external consumer data and information sources (ECDIS) or AI system components that correlate with protected classes and to validate that the correlation is not driving the adverse outcome. The 2026 carrier discipline is to maintain a per-variable proxy-correlation report - for each variable in the accelerated-UW rule set, a documented correlation analysis against race, ethnicity (typically estimated via Bayesian Improved Surname Geocoding with documented limitations), sex, and age. The reason-code memo references the proxy-correlation report by version; the chief compliance officer's countersignature attests that the references are current.

The FCRA Pre-Notice and Adverse-Action Letter

FCRA §615 governs adverse-action notices when a consumer report from a consumer reporting agency contributes to an adverse action. The LexisNexis MVR pull, the Milliman IntelliScript Rx report, the MIB code check, and the LexisNexis Risk Solutions ECDIS data each meet the definition of a consumer report under FCRA when used for life-insurance underwriting. A knockout that routes the case to traditional underwriting is not itself an adverse action - the case continues and the applicant has not yet been denied or rated. An eventual decline, a rated offer above the applied-for class, or a counteroffer at a higher premium is an adverse action and triggers FCRA §615 notice obligations.

The pre-notice protocol many carriers follow: when the accelerated-UW knockout occurs, send the applicant a courtesy notification that the case has been routed to traditional underwriting and that additional information (paramed, APS) will be requested. The notification is not an FCRA adverse-action notice and does not need to identify the consumer reporting agencies. When traditional underwriting concludes with an adverse action, the formal FCRA §615 notice issues: it identifies the carrier, states the adverse action, names the consumer reporting agencies that provided information (LexisNexis Insurance Solutions, MIB Group Inc., Milliman IntelliScript), provides the applicant's right to a free file disclosure from each agency within 60 days, provides the right to dispute the accuracy or completeness of the information, and provides the agency contact information. AI can draft the letter against the carrier's filed template; the underwriter and the compliance reviewer verify the agency identifications, the adverse-action description, and the absence of any medical-information disclosure that would violate the carrier's Notice and Affirmative Authorization (HIPAA authorization for medical information in life-insurance underwriting).

Protected-Class Proxy Separation in Practice

The 2026 enforcement focus on protected-class proxies has shifted from theoretical possibility to documented testing requirement. Colorado Reg 10-1-1 for life insurance requires carriers to maintain an algorithm inventory that documents the variables used in the accelerated-UW model, the data sources, and the bias-testing methodology. NY DFS Circular Letter 2024-7's proxy test is operationalized through quarterly reports demonstrating that adverse outcomes do not vary systematically by race or ethnicity beyond the actuarially supportable variation.

The mechanics on James Cordero's file: each variable invoked by the Magnum rules - MVR speeding-violation count, Rx atorvastatin presence, Rx sertraline presence, Rx lorazepam non-disclosure, MIB code 670 prior report - must have a documented per-variable correlation report against estimated race/ethnicity, sex, and age. The variable's contribution to mortality prediction must exceed the carrier's threshold for actuarial justification; the variable's correlation with protected-class status must be below the carrier's proxy threshold or, if above, must have a documented business-justification analysis. The accelerated-UW platform vendors (Swiss Re, RGA, SCOR, Munich Re) maintain platform-level proxy documentation; the carrier maintains carrier-specific documentation reflecting its rule customization. The audit trail is the bridge between the platform's documentation and the carrier's filed underwriting guidelines.

The File Note, the Reg 10-1-1 Inventory, and the Treaty Disclosure

The case file on James Cordero closes with three documentation artifacts beyond the knockout memo. First, the file note in the policy administration system (typically LifePRO, OIPA, or a carrier-built platform) records the knockout decision, the rule citations, the routing to traditional UW, the paramed and APS orders, and the model and version stamp (Magnum rules version 2026.Q1, model version 11.4.2). Second, the Colorado Reg 10-1-1 algorithm-inventory entry - if the carrier is admitted in Colorado and writes life insurance there - updates the per-case count for the rules invoked, supporting the quarterly inventory submission. Third, the reinsurance treaty disclosure - Swiss Re, RGA, SCOR, or Munich Re as the platform-providing reinsurer receives aggregated knockout statistics under the treaty's reporting requirement, supporting the reinsurer's mortality-experience analysis and its rate-development for the next treaty cycle.

The discipline that separates well-run accelerated-UW operations from operationally exposed ones is the consistency of the chain: rule citation → reason-code memo → file note → algorithm inventory → treaty disclosure. A knockout where the rule citation in the reason-code memo does not match the platform's rule output, or where the file note references a different platform version than the rule citation, or where the algorithm-inventory entry omits the case is a documentation defect that audits surface and that regulators question. AI compresses the documentation work; the underwriter, medical director, and chief compliance officer's countersignatures attest that the chain is intact.

Key Takeaways

• Accelerated underwriting on a $750,000 term-life case relies on five data feeds - LexisNexis MVR, Milliman IntelliScript Rx, MIB code check, ECDIS attributes with LexisNexis Risk Solutions overlay, and the carrier's internal mortality model - routed through Swiss Re Magnum, RGA AURA NEXT, SCOR Velogica, or Munich Re's risk-assessment platform. 55-70% of clean cases bind on the accelerated path; 18-22% knock out to traditional UW; 4-7% decline.
• The three dominant platforms - Magnum, AURA NEXT, Velogica - converge on the same operational outcome for material rule violations (MIB code 670 prior report, undisclosed Rx) but cite different rule IDs and produce different documentation envelopes. The carrier picks one platform as the system of record per product; the audit trail rests on that platform's rule citations.
• The knockout reason-code memo has six structural sections: applicant identification, data feeds consulted with pull dates, rule citations with debit values, knockout decision and routing, protected-class proxy separation, underwriter and medical-director sign-off. NAIC Model Bulletin §4 and Colorado Reg 10-1-1 expect the memo on every adverse-direction decision.
• An accelerated-UW knockout is not itself an FCRA §615 adverse action - the case continues to traditional UW. A courtesy pre-notice may issue at knockout; the formal FCRA §615 adverse-action notice issues only if traditional UW concludes with a decline, a rate-up, or a counteroffer.
• The FCRA §615 notice identifies LexisNexis Insurance Solutions, MIB Group Inc., and Milliman IntelliScript as consumer reporting agencies, provides the 60-day free-file-disclosure right, and provides the dispute right. No medical information may be disclosed in the notice beyond what the Notice and Affirmative Authorization covers.
• Protected-class proxy separation is documented at the per-variable level: each rule input must have a correlation report against estimated race/ethnicity (via BISG with limitations documented), sex, and age, plus an actuarial-justification analysis. NY DFS Circular Letter 2024-7's proxy test is operationalized through quarterly reports; Colorado Reg 10-1-1 requires algorithm-inventory documentation.
• The case-closing chain is rule citation → reason-code memo → file note in LifePRO/OIPA → Reg 10-1-1 algorithm-inventory entry → treaty disclosure to the platform-providing reinsurer. Inconsistency anywhere in the chain is the audit finding regulators surface.
• The 47-year-old James Cordero case bound back into traditional underwriting at +85 mortality points equivalent, with paramed and APS-cardiology ordered. The downstream decision - preferred, standard, table-rate, decline - emerges from the paramed and APS evidence with FCRA §615 notice triggering if adverse.